Vivo Bio Tech Ltd

Vivo Bio Tech Ltd’s share price declined to a fresh 52-week low of ₹16.15 on 18 Sep 2026, marking a significant downturn amid persistent underperformance relative to its sector and broader market indices.

Vivo Bio Tech Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 18 September 2026, providing investors with the latest insights into the company’s performance and outlook.

Vivo Bio Tech Ltd’s share price declined to a fresh 52-week low of ₹16.21 on 16 Sep 2026, marking a significant downturn for the pharmaceuticals and biotechnology company. This new low reflects ongoing pressures on the stock, which has underperformed both its sector and broader market indices over the past year.

Vivo Bio Tech Ltd’s stock price declined to a fresh 52-week low of Rs.16.24 on 11 September 2026, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed its sector and broader market indices, reflecting persistent challenges in financial performance and investor confidence.

Vivo Bio Tech Ltd’s stock price declined to a fresh 52-week low of Rs.16.45 on 10 September 2026, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed both its sector and broader market indices, reflecting persistent pressures on the company’s financial and market standing.

Vivo Bio Tech Ltd’s stock price declined sharply to a new 52-week low of Rs.17.41 on 1 September 2026, marking a significant milestone in its ongoing downward trajectory. The stock underperformed its sector and broader market indices despite opening the day with a positive gap, reflecting persistent pressures on the company’s valuation and fundamentals.

Vivo Bio Tech Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

While the broader market indices edged higher, Vivo Bio Tech Ltd succumbed to selling pressure, hitting a fresh 52-week low of Rs 18 on 21 Aug 2026. This decline marks a near 59.5% drop from its 52-week high of Rs 43.35, underscoring a pronounced divergence from the market's modest gains.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 August 2026, providing investors with the latest insights into its performance and outlook.

For the ninth consecutive session, Vivo Bio Tech Ltd. has closed lower, culminating in a fresh 52-week low of Rs 18.36 on 29 Jul 2026. This persistent decline has dragged the stock down by 12.89% over this period, sharply underperforming its sector and broader indices.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 29 July 2026, providing investors with the latest insights into the stock’s performance and outlook.

Vivo Bio Tech Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended June 2026, signalling a pause in its recent downward trend. Despite achieving its highest quarterly net sales and improved operational metrics, the company continues to grapple with margin pressures and a subdued return on capital employed, reflecting ongoing challenges in its business environment.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 July 2026, providing investors with the most recent and relevant data to assess the company’s outlook.

Vivo Bio Tech Limited, a contract research organisation specialising in drug development services, reported a concerning Q1 FY27 performance with net profit collapsing 85.82% year-on-year to ₹0.19 crores despite modest revenue growth. The micro-cap pharmaceutical services company, with a market capitalisation of ₹54.00 crores, saw its stock decline 4.72% to ₹24.00 following the results announcement, extending its bearish trend that has persisted since June 2026.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 June 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 30 June 2026, providing investors with the latest view of the company’s position in the market.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 June 2026, providing investors with the latest insights into the company’s performance and outlook.